Semaglutide ke lithethefatsi tse theolang tsoekere e entsoeng ke Novo Nordisk bakeng sa kalafo ea lefu la tsoekere la mofuta oa 2. Ka Phuptjane 2021, FDA e amohetse Semaglutide bakeng sa ho bapatsa e le sethethefatsi sa tahlehelo ea boima ba 'mele (lebitso la khoebo la Wegovy). Lithethefatsi ke glucagon-like peptide 1 (GLP-1) receptor agonist e ka etsisang liphello tsa eona, ea fokotsa tlala, 'me kahoo e fokotsa ho ja lijo le lik'halori, kahoo e sebetsa ho theola boima ba' mele.
Ntle le ho sebelisoa ho phekola lefu la tsoekere la mofuta oa 2 le botenya, Semaglutide e boetse e fumanoe ho sireletsa bophelo bo botle ba pelo, ho fokotsa kotsi ea kankere, le ho thusa ho khaotsa ho noa. Ho phaella moo, liphuputso tse peli tsa morao tjena li bontšitse hore Semaglutide e ka boela ea fokotsa kotsi ea lefu le sa foleng la liphio le lefu la Alzheimer's.
Liphuputso tse fetileng li bontšitse hore ho lahleheloa ke boima ba 'mele ho ka imolla matšoao a knee osteoarthritis (ho akarelletsa le ho imolla bohloko). Leha ho le joalo, litlamorao tsa lithethefatsi tsa GLP-1 receptor agonist tsa tahlehelo ea boima ba 'mele joalo ka Semaglutide ka litholoana tsa knee osteoarthritis ho batho ba batenya ha li so ithutoe ka botlalo.
Ka October 30, 2024, bafuputsi ba Univesithing ea Copenhagen le Novo Nordisk ba ile ba hatisa pampiri ea lipatlisiso e nang le sehlooho se reng: Hang-Beke le beke Semaglutide ho Batho ba nang le Botenya le Knee Osteoarthritis ho New England Journal of Medicine (NEJM), koranta e phahameng ea machaba ea bongaka.
Thuto ena ea kliniki e bontšitse hore semaglutide e ka fokotsa boima ba 'mele haholo' me ea fokotsa haholo bohloko bo bakoang ke ramatiki ea lengole e amanang le botenya (phello ea analgesic e lekana le ea li-opioids), le ho ntlafatsa bokhoni ba bona ba ho kenya letsoho lipapaling. Hape ke lekhetlo la pele ho netefatsoa hore mofuta o mocha oa lithethefatsi tsa ho theola boima ba 'mele, e leng GLP-1 receptor agonist, o netefalitsoe ho phekola ramatiki.
Nako ea poso: Feb-27-2025